A phase II trial of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial - Williamson, S K; Moon, J; Huang, C H (Journal of Clinical Oncology, 2006)
et al.